Drug Central

Drug results: 15

acetylcholine	A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. Miochol-E (acetylcholine chloride intraocular solution) is used to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required.
botulinum toxin type A	Botulinum toxin type A (Clostridium botulinum neurotoxin) blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within the nerve endings, thereby leading to denervation of the muscle and a flaccid paralysis.
methacholine	A quaternary ammonium parasympathomimetic agent with the muscarinic actions of ACETYLCHOLINE. It is hydrolyzed by ACETYLCHOLINESTERASE at a considerably slower rate than ACETYLCHOLINE and is more resistant to hydrolysis by nonspecific CHOLINESTERASES so that its actions are more prolonged. It is used as a parasympathomimetic bronchoconstrictor agent and as a diagnostic aid for bronchial asthma. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1116)
letibotulinumtoxina	LetibotulinumtoxinA-wlbg is an acetylcholine release inhibitor and neuromuscular blocking agent. LetibotulinumtoxinA-wlbg blocks peripheral cholinergic transmission at the neuromuscular junction by inhibiting acetylcholine release from presynaptic nerve terminals.
loperamide	One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.
amifampridine	4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
acotiamide	A prokinetic agent with gastrointestinal (GI) motility-enhancing activity. Although the exact mechanism by which acotiamide exerts its effect has yet to be fully elucidated, this agent appears to inhibit acetylcholinesterase (AchE), an enzyme responsible for the breakdown of acetylcholine (Ach). Increased Ach concentrations lead to an improvement of gastric emptying and GI motility and eventually to a reduction of dyspepsia symptoms.
oxybutynin	Oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle. Oxybutynin is a racemic (50:50) mixture of R- and S-isomers. Antimuscarinic activity resides predominantly in the R-isomer. The R-isomer of oxybutynin shows greater selectivity for the M1 and M3 muscarinic subtypes (predominant in bladder detrusor muscle and parotid gland) compared to the M2 subtype (predominant in cardiac tissue).
mosapride	Mosapride is a 5-HT4 receptor agonist which increases the release of acetylcholine and stimulates GI motility.
pitolisant	Pitolisant is a potent, orally active histamine H3-receptor antagonist/inverse agonist which, via its blockade of histamine auto-receptors enhances the activity of brain histaminergic neurons, a major arousal system with widespread projections to the whole brain. Pitolisant also modulates various neurotransmitter systems, increasing acetylcholine, noradrenaline and dopamine release in the brain.
prabotulinumtoxinA	PrabotulinumtoxinA-xvfs is an acetylcholine release inhibitor and a neuromuscular blocking agent
glycopyrronium bromide	Glycopyrrolate is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine and acetylcholine induced bronchoconstrictive effects was dose-dependent and lasted longer than 24 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of glycopyrrolate is predominantly a site-specific effect.
linopirdine	acetylcholine releasing drug
revefenacin	Revefenacin is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo models, prevention of methacholine- and acetylcholine-induced bronchoconstrictive effects was dose-dependent and lasted longer than 24 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of revefenacin is predominantly a site-specific effect.
choline	A basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.

DrugCentral Search Overview

Drug search example:

Generic drug names, drug synonyms, trade names terms can be used to search for drugs. Example search for Lipitor can query using either “Atorvastatin” or “Lipitor”.A comprehensive list of drug development codes and salt or ester forms are also stored in the database and can be used as search terms, for example search for "rosuvastatin" the following terms can be used: "rosuvastatin calcium" or "ZD4522".

Disease search example:

Supported disease terms are SNOMED-CT and OMOP vocabulary terms. Disease annotations for drugs approved before 2012 originate from OMOP vocabulary mappings. For drugs approved after 2012 disease annotations are extracted manually from approved drug labels and mapped to SNOMED-CT concepts.

Example search for “Chronic Hepatitis C” returns the list of antiviral drugs indicated to treat “Chronic Hepatitis C” followed by drugs contra-indicated in hepatitis C.

Medical (off label) uses suggestion form
Off label Uses Form
New! Substructure & Similarity search:
The current update supports chemical substructure and similarity searching powered by RDKit. Entering a SMILES or SMARTS string in the DrugCentral search bar launches a chemical search that finds matching compounds in DrugCentral. E.g., N1cnccc1. SMILES strings can be located on all Drug Cards under "Description". Also the JSME Molecular Editor has been integrated to support graphical molecular input.

FDA Adverse Event Reporting System:
The 2021 DrugCentral update, we separately calculated FAERS for men and women to enable research on sex differences in drug safety. The 2022 version goes further by computing adverse drug event scores granulated by age: pediatric data (FAERS_PED) covers patients from 1 day to 17 years, and geriatric data (FAERS_GER) focuses on elderly patients over 65 years of age, respectively. Female, Male, Geriatric & Pediatrics. E.g., amfetamine

Target Cards:
To perform a target card search enter a Uniprot target Accession ID e.g., P23975. The target cards depict the "Accession", "Swissprot", "Organism", "Gene" & "Target class" followed by "Drug relations" where the drugs "Bioactivity mechanism-of-actions" are identified.

Target search example:
Supported target search terms are HUGO gene symbols, Uniprot accessions and target names, and Swissprot identifiers. Example search for drugs targeting Mu-type opioid receptor can be run using either of the terms: “OPRM1”, P35372, “OPRM_HUMAN”, full or partial Uniprot target name. Returned drugs are ranked using the following criteria: top ranked drugs have mechanism of action target Mu-type opioid receptor, next in the list are drugs with potencies measured against this receptor.

In collaboration with the IDG
Veterinary Drugs, Uses & Products:

Drug Central now contains Veterinary Drugs, Uses & Products. The current update adds 1805 bioactivities for 226 veterinary drugs and 804 targets. DrugCentral veterinary data contains application numbers and types, trade names, applicant names, and prescription types for 1492 drug products as referenced in FDA’s Green Book. DrugCentral currently holds 1664 indications (pairs of drug and concept names) for 34 species. Dogs, cattle, and cats sum up to 63% of the indications covered by 193 veterinary drugs. Veterinary Drug Use can be found on each drug card by selecting the sub menu link: 🐶 Veterinary Use on the drug card. E.g., enrofloxacin
Pharmacologic action search example:

Supported pharmacologic action terms are MeSH, FDA [EPC, MoA, PE], ChEBI action roles.

Example search for “HMG-CoA Reductase Inhibitor” FDA EPC term for statin drugs returns list of all statin drugs classified by FDA as HMG-CoA reductase inhibitors.

Ranked result list is annotated with 4 level ranking system ordered from highest to lowest:

A - query term matched drug name or synonyms, mechanism of action target, or drug indication.

B - query term matched disease term in drug contraindications or off-label uses, targets listed in drug bioactivity profiles (not MoA targets), or pharmacologic action descriptions.

C - query term matched short drug description text.

D - query term matched full text in FDA drug labels.

Citing DrugCentral © 2026. License